Cargando…

Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis

BACKGROUND: Hyperlipidemia is a metabolic disease characterized by elevated levels of blood lipids and lipoproteins and a major pathogenic factor of atherosclerosis. In China, Erchen decoction (ECD) has been widely used to treat hyperlipidemia. However, there is no systematic review found. In order...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Huan, Xiong, Min, Zhu, Wenyu, Shen, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572033/
https://www.ncbi.nlm.nih.gov/pubmed/33080674
http://dx.doi.org/10.1097/MD.0000000000022374
_version_ 1783597265267458048
author Luo, Huan
Xiong, Min
Zhu, Wenyu
Shen, Tao
author_facet Luo, Huan
Xiong, Min
Zhu, Wenyu
Shen, Tao
author_sort Luo, Huan
collection PubMed
description BACKGROUND: Hyperlipidemia is a metabolic disease characterized by elevated levels of blood lipids and lipoproteins and a major pathogenic factor of atherosclerosis. In China, Erchen decoction (ECD) has been widely used to treat hyperlipidemia. However, there is no systematic review found. In order to evaluate the efficacy and safety of ECD in the treatment of hyperlipidemia, we need to conduct a meta-analysis and systematic evaluation. METHODS: We will enroll the randomized controlled trials (RCTs) evaluating the effectiveness and safety of ECD in the treatment of hyperlipidemia. Data come mainly from 4 Chinese databases (China national knowledge infrastructure, Wanfang, Chinese biomedical literature database, and VIP Database) and 4 English databases (Pubmed, Embase excerpt medica database, Cochrane Library, and Web of science). The enrollment of RCTs is from the starting date of database establishment till September 30, 2020. Low density lipoprotein cholesterol is considered as the main indicator of the dyslipidemia, while the serum concentrations of total cholesterol, triglyceride, high density lipoprotein cholesterol, apolipoprotein A, and apolipoprotein B are regarded as the secondary indicators. There are Safety indicators including liver enzyme, kidney function and fasting blood glucose. The work such as selection of literature, data collection, quality evaluation of included literature, and assessment of publication bias will be conducted by 2 independent researchers. Meta-analysis will be performed by RevMan 5.0 software. RESULTS: This study will provide high-quality evidence for the effectiveness and safety of ECD in the treatment of hyperlipidemia. CONCLUSION: The results of the study will help us determine whether ECD can effectively treat hyperlipidemia. ETHICS AND DISSEMINATION: This study does not require ethical approval. We will disseminate our findings by publishing results in a peer-reviewed journal. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/GZ69F
format Online
Article
Text
id pubmed-7572033
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75720332020-10-29 Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis Luo, Huan Xiong, Min Zhu, Wenyu Shen, Tao Medicine (Baltimore) 3800 BACKGROUND: Hyperlipidemia is a metabolic disease characterized by elevated levels of blood lipids and lipoproteins and a major pathogenic factor of atherosclerosis. In China, Erchen decoction (ECD) has been widely used to treat hyperlipidemia. However, there is no systematic review found. In order to evaluate the efficacy and safety of ECD in the treatment of hyperlipidemia, we need to conduct a meta-analysis and systematic evaluation. METHODS: We will enroll the randomized controlled trials (RCTs) evaluating the effectiveness and safety of ECD in the treatment of hyperlipidemia. Data come mainly from 4 Chinese databases (China national knowledge infrastructure, Wanfang, Chinese biomedical literature database, and VIP Database) and 4 English databases (Pubmed, Embase excerpt medica database, Cochrane Library, and Web of science). The enrollment of RCTs is from the starting date of database establishment till September 30, 2020. Low density lipoprotein cholesterol is considered as the main indicator of the dyslipidemia, while the serum concentrations of total cholesterol, triglyceride, high density lipoprotein cholesterol, apolipoprotein A, and apolipoprotein B are regarded as the secondary indicators. There are Safety indicators including liver enzyme, kidney function and fasting blood glucose. The work such as selection of literature, data collection, quality evaluation of included literature, and assessment of publication bias will be conducted by 2 independent researchers. Meta-analysis will be performed by RevMan 5.0 software. RESULTS: This study will provide high-quality evidence for the effectiveness and safety of ECD in the treatment of hyperlipidemia. CONCLUSION: The results of the study will help us determine whether ECD can effectively treat hyperlipidemia. ETHICS AND DISSEMINATION: This study does not require ethical approval. We will disseminate our findings by publishing results in a peer-reviewed journal. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/GZ69F Lippincott Williams & Wilkins 2020-10-16 /pmc/articles/PMC7572033/ /pubmed/33080674 http://dx.doi.org/10.1097/MD.0000000000022374 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 3800
Luo, Huan
Xiong, Min
Zhu, Wenyu
Shen, Tao
Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis
title Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis
title_full Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis
title_fullStr Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis
title_full_unstemmed Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis
title_short Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis
title_sort erchen decoction for hyperlipemia: protocol for a systematic review and meta-analysis
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572033/
https://www.ncbi.nlm.nih.gov/pubmed/33080674
http://dx.doi.org/10.1097/MD.0000000000022374
work_keys_str_mv AT luohuan erchendecoctionforhyperlipemiaprotocolforasystematicreviewandmetaanalysis
AT xiongmin erchendecoctionforhyperlipemiaprotocolforasystematicreviewandmetaanalysis
AT zhuwenyu erchendecoctionforhyperlipemiaprotocolforasystematicreviewandmetaanalysis
AT shentao erchendecoctionforhyperlipemiaprotocolforasystematicreviewandmetaanalysis